edgeX EDGEX in Transfidelity FIDEL tauschen

EdgeX ist eine dezentrale Trading-Plattform für Perpetuals, die die Geschwindigkeit und Leistungsfähigkeit zentralisierter Trading-Plattformen mit der Transparenz und Selbstverwahrung des dezentralen Finanzwesens verbindet. Die Plattform verfügt über eine Engine zum Offchain-Order-Matching mit Onchain-Abwicklung, die schnelles Trading mit geringer Latenz für eine breite Palette von Kryptos ermöglicht. Aufgrund einer Ticker-Kollision verwendet Coinbase für dieses Krypto den Ticker „EDGEX“ anstelle der Onchain- oder MiCA-Whitepaper-Bezeichnung „EDGE“. Diese Anpassung gewährleistet die Kompatibilität mit bestehenden Ressourcen auf unserer Plattform und vermeidet potenzielle Konflikte. Diese Änderung hat keine Auswirkung auf die Funktionalität oder den Wert des Basiswerts.

Neurodegenerative diseases such as Alzheimer's Disease are devastating conditions that impact millions globally. These diseases are driven by the misfolding and aggregation of proteins, which lead to brain cell death and cognitive decline. To make matters worse, as we age our cells become more error-prone, resulting in more errors during protein printing, causing proteins to clump together and form aggregates. Project Transfidelity aims to solve this by improving the accuracy of protein printing, preventing toxic aggregates from forming. Led by Dr. Dimitri Scherbakov and Dr. Rashid Akbergenov, with over 50 years of combined experience in the lab, we have identified two molecules that may improve the efficiency of protein production, potentially preventing protein aggregates, hypothesized to cause dementia. Despite the significant research funding allocated to neurodegenerative diseases, current therapies continue to treat the symptoms caused by the protein aggregates, with little progress made to stop or reverse disease. We’re trying to go after a potential root cause - rather than trying to clear aggregates once they are there, we aim to prevent them from forming in the first place by reducing the production of faulty proteins. With a clear path towards developing novel intellectual property (IP) and an ever-growing target market, we believe we are poised to make an impact on neurodegenerative disorders and the way we age.